If you liked this article you might like

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round
Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)
Bristol Myers Vies to Be King of Immune-Boosting Cancer Drugs with New Trial Update